anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a preparation method of a traditional Chinese medicine used for treating abdominal distension. The method is characterized in that: tuckahoe, stir-fried largehead atractylodes rhizome, stir-fried lablab, dried ginger, stink bug, raw malt, stir-fried chicken's gizzard-membrane, raw Mongolian milkvetch root, pilose asiabell root, banksian rose, officinal magnolia flower, common yam rhizome, stir-fried coix seed, balloonflower root, combined spicebush root, round cardamom fruit, raw dodder, white peony root, divaricate saposhnikovia, incised notopterygium rhizome and root, stir-fried fennel, officinal magnolia bark, stir-fried garden radish seed, areca peel, and curcuma rhizome prepared with vinegar are cleaned by washing and soaked in water for 30min; the materials are placed in a vessel such as a casserole, a ceramic pot, or a pottery pot; the materials are decocted twice, and obtained decoctions are mixed, wherein a total amount is 300-350ml. The traditional Chinese medicine is taken when warm. One preparation is taken a day, and is divided in two parts which are respectively taken after breakfast and supper. For a patient with administration difficulty, the preparation can be divided into a plurality of small parts which are taken a plurality of times. A treatment course comprises 7 preparations.
The present invention relates to nucleic acid sequences encoding Ostertagia ostertagi proteins and to parts of such nucleic acid sequences that encode an immunogenic fragment of such proteins, and to DNA fragments, recombinant DNA  molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof. The invention also relates to Ostertagia ostertagi proteins and immunogenic parts thereof encoded by such sequences.  Furthermore, the present invention relates to vaccines comprising such nucleic acid sequences and parts thereof, DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof, proteins or immunogenic parts thereof and antibodies against such proteins or immunogenic parts thereof. Also, the invention relates to the use of said proteins in vaccines and for the manufacture of vaccines. Moreover, the invention relates to the use of aid nucleic acid sequences, proteins or antibodies for diagnostic or vaccination purposes. Finally the invention relates to diagnostic kits comprising such nucleic acids, proteins or antibodies against such proteins.
Cadmium (Cd) is an environmental toxicant of worldwide public health significance. Diet is the main non-workplace Cd exposure source other than passive and active smoking. The intestinal absorption of Cd involves transporters for essential metals, notably iron and zinc. These transporters determine the Cd body burden because only a minuscule amount of Cd can be excreted each day. The International Agency for Research on Cancer listed Cd as a human lung carcinogen, but the current evidence suggests that the effects of Cd on cancer risk extend beyond the lung. A two-year bioassay demonstrated that Cd caused neoplasms in multiple tissues of mice. Also, several non-tumorigenic human cells transformed to malignant cells when they were exposed to a sublethal dose of Cd for a prolonged time. Cd does not directly damage DNA, but it influences gene expression through interactions with essential metals and various proteins. The present review highlights the epidemiological studies that connect an enhanced risk of various neoplastic diseases to chronic exposure to environmental Cd. Special emphasis is given to the impact of body iron stores on the absorption of Cd, and its implications for breast cancer prevention in highly susceptible groups of women. Resistance to cell death and other cancer phenotypes acquired during Cd-induced cancer cell transformation, under in vitro conditions, are briefly discussed. The potential role for the ZnT1 efflux transporter in the cellular acquisition of tolerance to Cd cytotoxicity is highlighted.
The invention relates to medicine and can be used for correcting mineral metabolism in an organism. Atomic absorption spectrometry (with electrothermal atomization), atomic emission spectrometry or inductively coupled plasma mass spectrometry is carried out on hair and/or nails. The levels of the following elements in the hair and/or nails are determined: Са, Со, Cr, Cu, K, Mg, Mn, Se, Zn. Abnormalities detected in the level of said elements are divided into four degrees, shown in Table 6. Deficits detected in the levels of said elements are corrected by prescribing preparations, the dosages of which are determined according to weight, age and the degree of abnormality in the level of the elements, as follows: in the case of a 1st-2nd degree abnormality, a person weighing 70 kg is given a preparation dosage in accordance with Table 7; children up to 10 years are given a third of the dosage; children of 10-15 years are given half the dosage; in the case of a 3rd degree abnormality, one third of the dosage is added to the value given in the table; in the case of a 4th degree abnormality, two thirds of the dosage is added; weight is also taken into consideration so that for every 20 kg over 70 kg, the dosage is increased by one third, and for every 20 kg under 70 kg, the dosage is reduced by one third. The method provides effective treatment of mineral metabolism disorders using a comprehensive approach with maximum consideration for factors affecting mineral metabolism, and with clear treatment criteria.
BACKGROUND: Simultaneous transcatheter mitral valve in valve (VIV) replacement and aortic valve replacement experience is limited. We report our initial experience with simultaneous transapical transcatheter aortic and mitral valve replacement in patients with severe valve dysfunction.
METHODS: A total of 8 patients had simultaneous transcatheter heart valve implants for severe mitral bioprosthesis failure (VIV), with a second valve procedure that included native aortic regurgitation (n = 3) or degenerated bioprostheses in the aortic position (n = 5). All patients were treated with a self-expandable J-valve transcatheter valve, using the transapical approach.
RESULTS: The mean age of the patients was 73.1 ± 6.2 years. The mean Society of Thoracic Surgeons score was 13.8 ± 6.3%. Device success was 100% according to Valve Academic Research Consortium-2 criteria. No other procedure-associated complications occurred, including left ventricular outflow tract obstruction and valve migration. The mean hospital lengths of stay after the procedure were 11.5 ± 8.0 days. No deaths occurred at 30 days. At a median follow-up period of 28.7 ± 22.3 months, no patients died. All patients were in New York Heart Association functional classes I-II. Echocardiographic parameters at follow-up showed a normofunctioning J valve in the mitral position and a mean max mitral flow velocity of 2.0 ± 0.5 m/s; the J valve in the aortic position was also normofunctioning, and the mean max aortic flow velocity was 2.3 ± 0.5 m/s.
CONCLUSION: Simultaneous transapical transcatheter aortic and mitral valve replacement using the self-expandable J valve appears to be a feasible and effective alternative to redo surgery.
This study will test the effects of a dyadic preventive intervention, Family Promoting Positive Emotion (F-PPE), for 8- to 12-year-old children of mothers with a history of major depressive disorder (MDD) with anhedonia. The study will first test F-PPE effects on child reward responsiveness (R61), and pending evidence of target engagement, effects on real-world experience of interest/pleasure and clinical symptoms of anhedonia will be evaluated in a second, larger clinical trial (R33). F-PPE was designed to increase child positive valence systems function through mother-child training in behavioral and cognitive skills to increase pleasant activities and attention towards/savoring the positive, individual and dyadic goals, and skills practice. For the R61 phase, eligible child participants (N=60 intervention completers) will complete an EEG assessment of neural reward responsiveness, as well as halfway through the intervention (4 weeks) to determine dose effects. Children and their biological mothers will be randomly assigned to 8 sessions of F-PPE or a psychoeducation comparison condition (groups will be matched on child sex and baseline RewP). Both interventions will be administered through individual telehealth sessions with a masters- or doctoral-level clinician under the supervision of the PIs. To ensure treatment fidelity, videotaped sessions will be reviewed for adherence to the protocol, clinicians will participate in weekly group supervision, and supervisors will randomly review recorded sessions for ratings of treatment adherence.
A skin care composition comprises an oilin-water emulsion, containing a water-soluble polypeptide in the aqueous phase, and also containing a stabilising amount of a preservative system comprising methyl-p-hydroxybenzoate, propyl-p-hydroxybenzoate and sodium ethylmercurithiosalicylate. Preferably the constituents of the preservative are in the amounts of 0.08-0.20%, 0.03-0.1% and 0.01 -0.03% by weight of the total composition respectively together with 0.8-2% of a watersoluble polypeptide of molecular weight 1500-5000. 0.15-0.5% of allantoin and 2-3% of squalane may be present, the pH of the composition preferably being 6.5-8.5. An anionic surfactant, e.g. sodium lauryl sulphate, may be present. Emollients, moisturizers and humectants may be present, as may lanolin or acetylated lanolin alcohol. Such polypeptides may conveniently be made by hydrolysis of proteins from animal skins, e.g. from tanned leather.
The purpose of this study is to evaluate the safety and performance of HFOV modes of the Servo-n ventilator in neonates and infants. This is a prospective, observational, single-arm (i.e., non-controlled) and multi-center PMCF study in neonates and infants between 0.3 to 8 kg. All study procedures are within each hospital's routine clinical practice.The primary endpoints includes variables which are routinely used per clinical practice for assessing the status of patient's ventilation and oxygenation, respectively. Secondary endpoints are used to evaluate safety of Servo-n HFOV during its use by assessing rates of adverse event/ device deficiencies related to the Servo-n HFOV device, and by assessing rates of mortality, Bronchopulmonary Dysplasia (BPD) and Retinopathy at Intensive Care Unit (ICU) discharge. Data collection will take place up to 24 hours prior to HFOV treatment, during HFOV and up to ICU discharge. Additional general data such as ventilator settings, reasons for initiating/terminating HFOV treatment and demographics will also be recorded.
PROBLEM TO BE SOLVED: To obtain the subject bathing agent which can rapidly remove residual chlorine in the tap water, can enhance and maintain the sterilization action, and is useful and safe for human bodies, by including an iodine compound which reacts with chlorine in an aqueous system to release iodine. SOLUTION: This bathing agent for bath water comprising tap water contains an iodine compound which reacts with chlorine in an aqueous system to release iodine. The bathing agent may further contain ingredients usually contained in bathing agents, such as a perfume. The iodine compound is preferably a water-soluble inorganic iodine compound, especially potassium iodide or sodium iodide. When the iodine compound is added to the tap water, the iodine ions are changed into iodine (I2) which is released, and simultaneously change (residual) chlorine in tap water into an injurious chloride compound. The amount of the iodine compound to be added is determined in response to the amount of the tap water (bath water) and to the concentration of the residual chlorine under the consideration of the amount of the residual chlorine to be removed and the iodine to be released.  Since the released iodine yellows the tap water (bath water), the amount of the bathing agent may be adjusted in response to the density of the color of the water.
The disease burden of coronary artery diseases (CAD) remains one of the most serious and persistent health problems for the investigator's nation. One out of every six deaths in the United States is solely attributed to CAD. Every year, nearly 7 million adults visit the emergency department (ED), reporting chest pain associated with a possible heart attack. Being able to immediately differentiate between cardiac (ischemic) and non-cardiac chest pain is crucial and improves survival and reduces disability for thousands of people. The electrocardiogram (ECG) is an indispensable tool to detect ischemia and is the first tool available for initial chest pain evaluation in EDs and, even earlier, by paramedics in the field. Current guidelines focus on ST elevation (STE) to identify patients most in need of immediate treatment. Unfortunately, STE only occurs in one-third of all patients with acute myocardial infarction, and missed myocardial infarction remains one of the highest sources of medical malpractice in emergency medicine. This translates to delayed treatment for nearly 1 million heart attacks until costly, time-consuming, and more invasive diagnostics are conducted and interpreted. Prior work by the investigators has explored novel ECG markers, other than STE, and noted that the dynamic ECG changes in these markers can improve diagnosis of acute coronary syndromes (ACS). This prior data showed that myocardial ischemia disturbs the ventricular repolarization process and results in quantifiable distortions of T waves on the surface 12-lead ECG prior to any displacement of the ST segment. Markers of T wave abnormalities, therefore, can identify patients with ischemic chest pain in the absence of acute ST changes very early in the triage process. The current study plans to evaluate how these novel ischemic ECG changes evolve over time during the acute phase of the coronary syndromes. This approach has a high potential for improving the speed and accuracy of diagnosing ACS and is potentially deployable in any ED or ambulance to greatly accelerate definitive treatment, thereby reducing morbidity and mortality for thousands of patients each year.
[PROBLEMS] To provide a method of regenerating or repairing a damaged tissue by using adrenomedulin. It is also intended to provide a drug for regenerating or repairing a damaged tissue which comprises adrenomedulin as the active ingredient. [MEANS FOR SOLVING PROBLEMS] To solve the above problems, adrenomedulin (hereinafter referred to as AM) or physiological saline is administered to C57BL/6 mice and monocytes and Sca-1-positive cells in the blood are counted. As a result, it is clarified that AM causes increases in the monocyte count and the stem cell antigen-1-positive cell count. It is also found out that, by administering AM to an emphysema model mouse and an acute cardiac infarction model rat, the number of bone marrow-origin cells migrating to a damaged tissue and fixing thereto is increased and that the mobilized bone marrow cells differentiate into vessels, lung alveoli and cardiac muscles in the lesion site. Moreover, reduction in the infarct size, inhibition of the enlargement of lung alveolus diameter and improvements in the functions of individual organs are confirmed in the cardiac infarction and emphysema models.
The legalization of recreational marijuana in Alaska, Colorado, Oregon, and Washington State is the most dramatic change in U.S. substance abuse policy since the end of Prohibition. These states are implementing regulatory and enforcement systems for the retail sales of recreational marijuana to adults 21 years or older, akin to state controls on the sale of alcohol. In 2013, the U.S. Department of Justice (DOJ) issued directives that it would monitor whether these states implemented strong and effective regulatory and enforcement systems that among other DOJ priorities, prevented distribution of marijuana to youth. A retail sales intervention that has been effective at reducing illegal alcohol sales to minors (and intoxicated patrons) is alcoholic beverage server training (or responsible beverage service training). Recently, Colorado enacted a law for incentivized responsible marijuana vendor training, Oregon will require responsible marijuana vendor training, and Washington State may incentivize it. In this study, we propose to 1) produce the TrainToTend online responsible marijuana vendor training presenting retail marijuana sales laws, methods for checking IDs and preventing third party sales, the health effects of marijuana (e.g., fetal exposure; safe storage), customer service (e.g., driving under the influence; refusing sales to minors), and rules of the trade (e.g., inventory tracking and safety procedures) and 2) conduct a randomized trial on the TrainToTend training with a sample of retail recreational marijuana stores in Colorado, Oregon and Washington State (n=150) that are randomly assigned to have their employees complete the TrainToTend training (experimental group) or receive usual and customary sales training by store managers (no intervention control group). The effect of the TrainToTend training on responsible sales practices will be assessed by changes in recreational marijuana purchase attempts by pseudo-underage patrons (i.e., young-appearing customers without apparently valid IDs) at each store measured at 3-month follow-up and 9-month follow-up relative to baseline.
Impaired Liver Function

Do not use Tri-Sprintec in women with liver disease, such as acute viral hepatitis or severe (decompensated) cirrhosis of liver [see Contraindications (4)]. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue Tri-Sprintec if jaundice develops. 

Liver Tumors 

Tri-Sprintec is contraindicated in women with benign and malignant liver tumors [see Contraindications (4)]. Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage. 

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) COC users. However, the risk of liver cancers in COC users is less than one case per million users.
At entry, patients will have a complete history and physical, blood tests, ultrasound, and will complete questionnaires. Eligible patients will take Thalidomide 400 mg once a day in the evening. Patients will start a dose of 100 mg per day for two weeks, increasing by 100 mg per day every two weeks to a maximum dose of 400 mg per day for 6 months. Patients will return at 6 months for an evaluation, blood tests and completion of questionnaires. Blood tests will be performed by mailed-in kits at 3 months. Patients will receive weekly phone calls for the first 2 months and bi-monthly thereafter.
PROBLEM TO BE SOLVED: To obtain a pharmaceutical preparation capable of reducing or suppressing toxicity due to an anticancer agent without lowering anticancer action by use thereof in combination with the anticancer agent. SOLUTION: This toxicity reducing agent contains a bacterial cell (e.g. Enterococcus faecalis NF-1011) of a bacterium belonging to the genus Enterococcus or its treated material as an active ingredient. A carrier such as starch or lactose, a vehicle, a binder, a disintegrator, a lubricant, a stabilizer or a flavoring agent is added to the agent and the mixture is prepared in a tablet, granule, etc., by ordinary method. The agent is administered at a daily dose of 0.002-0.1g/kg.weight.adult as an active ingredient in one to several portions. The agent is effective in reducing adverse effect due to anticancer agents, especially renal toxicity after administering cisplatin. The bacterial cell is obtained by culturing enterococcus faecalis strain under aerobic conditions.
Screening tests for healthy volunteers included physical examination, vital signs, laboratory will test (hematology, blood chemistry, and urinalysis), and a 12-lead electrocardiograms. A psychiatric interview with the Structured Clinical Interview for text revision of the Diagnostic and Statistical Manual of Mental Disorders -IV(DSM-IV-TR) Axis I disorders, Research Version, Nonpatient Edition (SCID-I/NP) (First et al. 2002) will be conducted. Subjects with any medically significant abnormality on investigations and/or psychiatric disease will be excluded. Also, healthy control group will take a PET scan at 0, 2, 4, 6, and 8 week and clinical scales at baseline.
Insomnia: measured by PSQI scale. The scale was developed by Buysse et al, a neurologist at the University of Pittsburgh, USA, and has an overall internal consistency Cronbach's ɑ coefficient of 0.83.The scale was used to assess the quality of sleep of an individual in the last month, and consists of 19 self-assessed and 5 other-assessed entries, for a total of 24 items, where the 19th entry and the five other-assessed entries do not participate in the scoring. The 18 scoring items include seven dimensions: subjective sleep quality, time to sleep, sleep efficiency, sleep disorders, hypnotic drug use, and daytime functioning. Each dimension is scored on a scale of 0-3, and the cumulative score is the total PSQI score, which ranges from 0-21, with higher scores indicating poorer sleep quality, and PSQI scores greater than 7 are considered clinical insomnia.

Physical activity: was measured using the Physical activity rating scale-3 (PARS-3). The scale has a revised by Liang Deqing et al. with a retest reliability of 0.82. The scale determines the amount of exercise in terms of intensity, time, and frequency of participation in physical activities. Exercise volume = exercise intensity × time × frequency, intensity and frequency are scored on a scale of 1 to 5, assigning 1 to 5 points respectively, and time is scored on a scale of 1 to 5, assigning 0 to 4 points respectively. The score range of the scale was 0-100 points, and the score of ≤19 points was low exercise, 20-42 points was medium exercise, and ≥43 points was high exercise.
Compositions arid methods are provided for the generation or treatment of chronic tympanic membrane perforation by modulation of HB-EGF activity. In the methods of the invention, a chronically perforated tympanic membrane is topically contacted with an effective dose of heparin binding-epidermal growth factor, HB-EGF, or an agent having HB-EGF activity, for a period of time sufficient to provide for improved healing of the membrane perforation. In some embodiments the dose of HBEGF is provided in a sustained release formulation; in other embodiments regular administration of a non-sustained release formulation is provided. In some embodiments, a sustained release formulation is biodegradable. In other embodiments sustained release is provided by a device, e.g. a pump or other release device.